| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1124596595 |
| P356 | DOI | 10.1016/J.CLINTHERA.2020.01.009 |
| P932 | PMC publication ID | 7102617 |
| P698 | PubMed publication ID | 32035643 |
| P2093 | author name string | M Anthony Moody | |
| Letitia D Jones | |||
| Amelia B Thompson | |||
| P2860 | cites work | The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens | Q22242262 |
| Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary Report | Q24289287 | ||
| Immune correlates of vaccine protection against HIV-1 acquisition | Q26778573 | ||
| Antibody responses to envelope glycoproteins in HIV-1 infection | Q26991572 | ||
| HIV‐1 neutralizing antibodies: understanding nature's pathways | Q27000480 | ||
| Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors | Q27643993 | ||
| Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env | Q27644383 | ||
| Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus | Q27644501 | ||
| Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design | Q27644646 | ||
| A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield | Q27675032 | ||
| Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody | Q27675207 | ||
| Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors | Q27677104 | ||
| Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization | Q27684578 | ||
| Retraction | Q74069921 | ||
| Scientists slam rationale behind largest HIV vaccine trial | Q79828713 | ||
| STEP study: disappointing, but not a failure | Q79899608 | ||
| Support for the RV144 HIV vaccine trial | Q80333468 | ||
| Structure-Guided Redesign Improves NFL HIV Env Trimer Integrity and Identifies an Inter-Protomer Disulfide Permitting Post-Expression Cleavage | Q90675709 | ||
| Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation | Q90899923 | ||
| Structure-Based Vaccine Antigen Design | Q91255522 | ||
| Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens | Q91678110 | ||
| Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence | Q92382176 | ||
| An Asymmetric Opening of HIV-1 Envelope Mediates Antibody-Dependent Cellular Cytotoxicity | Q93027703 | ||
| Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge | Q37287080 | ||
| HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies | Q37293480 | ||
| Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys | Q37355237 | ||
| Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments | Q37369561 | ||
| Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens | Q37456354 | ||
| Heterologous prime-boost vaccination. | Q37509586 | ||
| Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells | Q37573696 | ||
| Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge | Q37681765 | ||
| Broadly neutralizing antibodies against HIV-1: templates for a vaccine | Q38065391 | ||
| Gene therapy with an AAV vector expressing human IL-2 alters immune system homeostasis in humanized mice | Q38616032 | ||
| Covalent Linkage of HIV-1 Trimers to Synthetic Liposomes Elicits Improved B Cell and Antibody Responses | Q38737582 | ||
| Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation | Q38988188 | ||
| Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development | Q39108751 | ||
| Complex immune correlates of protection in HIV-1 vaccine efficacy trials | Q39108779 | ||
| Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand | Q39358681 | ||
| Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response | Q40043429 | ||
| Enhanced antibody half-life improves in vivo activity | Q40045495 | ||
| Open-label phase I clinical trial of Ad5-EBOV in Africans in China | Q40048316 | ||
| Modified mRNA Vaccines Protect against Zika Virus Infection | Q40049416 | ||
| Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge | Q40055103 | ||
| Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach | Q40198048 | ||
| Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial | Q40332276 | ||
| Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. | Q40429324 | ||
| Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. | Q40449526 | ||
| Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140. | Q40503064 | ||
| Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice | Q40589505 | ||
| Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design | Q40679052 | ||
| Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design | Q41042362 | ||
| Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. | Q41933482 | ||
| Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques | Q41933491 | ||
| DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA. | Q41995910 | ||
| Chimpanzee adenoviral vectors as vaccines for outbreak pathogens | Q44106019 | ||
| Stability of endogenous and added RNA in blood specimens, serum, and plasma | Q44153103 | ||
| Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. | Q44536209 | ||
| A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. | Q45409784 | ||
| Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers | Q45737847 | ||
| Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women | Q45747371 | ||
| Longitudinal Analysis of Human Immunodeficiency Virus Type 1‐Specific Cytotoxic T Lymphocyte Responses: A Predominant Gag‐Specific Response Is Associated with Nonprogressive Infection | Q45752981 | ||
| The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network | Q45853395 | ||
| Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. | Q45938142 | ||
| Adenovirus vectors as HIV-1 vaccines: where are we? What next? | Q45986030 | ||
| Public health. AIDS vaccine trial produces disappointment and confusion | Q46174067 | ||
| High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers | Q46272894 | ||
| Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models | Q47215738 | ||
| Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens | Q47232975 | ||
| Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. | Q47549492 | ||
| Neutralization tiers of HIV-1. | Q47562235 | ||
| mRNA vaccines - a new era in vaccinology | Q47736893 | ||
| HIV Immunogens: Affinity Is Key. | Q49990720 | ||
| Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants | Q51926211 | ||
| HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons | Q52036602 | ||
| Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. | Q52688325 | ||
| Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity | Q53081267 | ||
| Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. | Q54217790 | ||
| Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies. | Q54979433 | ||
| Fusion-competent vaccines: broad neutralization of primary isolates of HIV | Q56765810 | ||
| The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen | Q57094341 | ||
| Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes | Q58589975 | ||
| Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time | Q58598623 | ||
| Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial | Q58713726 | ||
| Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers | Q58721980 | ||
| Closing and opening holes in the glycan shield of HIV-1 envelope glycoprotein SOSIP trimers can redirect the neutralizing antibody response to the newly unmasked epitopes | Q59349684 | ||
| Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies | Q59353026 | ||
| Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth | Q60300903 | ||
| A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection | Q61813267 | ||
| Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA | Q63246643 | ||
| HIV/AIDS. Vaccine results lose significance under scrutiny | Q73095339 | ||
| Live attenuated vaccines: Historical successes and current challenges | Q28082036 | ||
| Edward Jenner's Inquiry; a bicentenary analysis | Q28297101 | ||
| A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies | Q28299280 | ||
| Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection | Q28304773 | ||
| Thermostability of Well-Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing Antibodies | Q28553360 | ||
| HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers | Q28647225 | ||
| Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination | Q28656365 | ||
| Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults | Q28740321 | ||
| Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial | Q28972526 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Broad neutralization coverage of HIV by multiple highly potent antibodies | Q29615361 | ||
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| Assessing vaccine effects in repeated low-dose challenge experiments. | Q30376557 | ||
| Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses | Q30401521 | ||
| Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort | Q33443744 | ||
| Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals | Q33594304 | ||
| Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies | Q33614365 | ||
| Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys | Q33712291 | ||
| Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates | Q33742529 | ||
| Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes | Q33743758 | ||
| HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies | Q33753573 | ||
| Antibody 10-1074 suppresses viremia in HIV-1-infected individuals | Q33786443 | ||
| Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1 | Q33883887 | ||
| Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys | Q33984182 | ||
| A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals | Q34047445 | ||
| Edward Jenner and the Eradication of Smallpox | Q34066116 | ||
| Vaccines: science, health, longevity, and wealth | Q34120026 | ||
| Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. | Q34214455 | ||
| Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag | Q34228487 | ||
| Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study | Q34240204 | ||
| B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study | Q34273373 | ||
| Public health. A sound rationale needed for phase III HIV-1 vaccine trials | Q34290243 | ||
| Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant | Q34301874 | ||
| Immune clearance of highly pathogenic SIV infection | Q34370314 | ||
| Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine | Q34373275 | ||
| HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption | Q34531858 | ||
| Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo | Q34593860 | ||
| Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239 | Q34651604 | ||
| Gene therapy using adeno-associated virus vectors | Q34852719 | ||
| Polyreactivity and autoreactivity among HIV-1 antibodies | Q34992787 | ||
| Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine | Q35009558 | ||
| Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1 | Q35122067 | ||
| "Once Bitten, Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination. | Q35219438 | ||
| Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion | Q35558828 | ||
| Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials | Q35611969 | ||
| Enhanced neonatal Fc receptor function improves protection against primate SHIV infection | Q35612850 | ||
| Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. | Q35641498 | ||
| Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors | Q35857221 | ||
| Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort | Q35894094 | ||
| HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen | Q35969973 | ||
| Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity | Q36094699 | ||
| Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens | Q36102994 | ||
| Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses | Q36118373 | ||
| Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. | Q36132706 | ||
| Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys | Q36300153 | ||
| Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization. | Q36334359 | ||
| Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens | Q36434196 | ||
| Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. | Q36489415 | ||
| HIV vaccines: new frontiers in vaccine development | Q36534852 | ||
| Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses | Q36693991 | ||
| Macaques vaccinated with live-attenuated SIV control replication of heterologous virus | Q36946545 | ||
| High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. | Q36957800 | ||
| Development of an Ad5H3 Chimera Using the "Antigen Capsid-Incorporation" Strategy for an Alternative Vaccination Approach | Q36966327 | ||
| Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation | Q36977531 | ||
| Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. | Q37060986 | ||
| Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery | Q37070349 | ||
| Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers | Q37123501 | ||
| Vaccines: correlates of vaccine-induced immunity | Q37193062 | ||
| Cytomegalovirus Vectors Violate CD8 + T Cell Epitope Recognition Paradigms | Q37278451 | ||
| P921 | main subject | vaccine engineering | Q14861085 |
| P577 | publication date | 2020-02-05 | |
| 2020-03-01 | |||
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Clinical Therapeutics | Q15716601 |
| P1476 | title | Innovations in HIV-1 Vaccine Design |
| Q100946403 | Self-amplifying RNA vaccines for infectious diseases | cites work | P2860 |
Search more.